Bjoern Traenkle

Bjoern Traenkle

Auto-generated profile, based on publicly available information

Bjoern Traenkle

NMI Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMartin V. Hamann
Martin V. Hamann
NBNiklas Beschorner
Niklas Beschorner
XVXuan-Khang Vu
Xuan-Khang Vu
IHIlona Hauber
Ilona Hauber
ULUlrike C. Lange
Ulrike C. Lange
JHJoachim Hauber
Joachim Hauber
Adeno-associated viruses (AAV) are considered non-pathogenic in humans, and thus have been developed into powerful vector platforms forin vivogene therapy. Although the various AAV serotypes display broad tropism, frequently infecting multiple tissues and cell types, vectors for specific and efficient targeting of human CD4+T lymphocytes are largely missing. In fact, a substantial translational bottleneck exists in the field of therapeutic gene transfer that would requirein vivodelivery into peripheral disease-related lymphocytes for subsequent genome editing. To solve this issue, capsid modification for retargeting AAV tropism, and in turn improving vector potency, is considered a promising strategy. Here, we genetically modified the minor AAV2 capsid proteins, VP1 and VP2, with a set of novel nanobodies with high-affinity for the human CD4 receptor. These novel vector variants demonstrated improved targeting of human CD4+cells, including primary human peripheral blood mononuclear cells (PBMC) and purified human CD4+T lymphocytes. Thus, the technical approach presented here provides a promising strategy for developing specific gene therapy vectors, particularly targeting disease-related peripheral blood CD4+leukocytes.

1 October 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
JMJulia Maier
Julia Maier
BTBjoern Traenkle
Bjoern Traenkle
Ulrich RothbauerUlrich Rothbauer
Ulrich Rothbauer
The epithelial–mesenchymal transition (EMT) is a complex cellular program involved in the progression of epithelial cancers to a metastatic stage. Along this process, epithelial traits are repressed in favor of a motile mesenchymal phenotype. A detailed characterization and monitoring of EMT-related processes is required for the design of screening strategies needed to develop novel antimetastatic therapies. Overexpression of the canonical EMT biomarker vimentin correlates with increased tumor growth and invasiveness, as well as with reduced patient survival across various epithelial cancers. Moreover, recent findings have demonstrated an active role of vimentin in regulating and reorganizing the cellular architecture toward a migratory and invasive phenotype. However, current studies suffer from a lack of appropriate methods to trace the induction and dynamics of vimentin in cell-based assays. Recently, we have reported a novel intrabody (chromobody)–based approach to study the spatiotemporal organization of endogenous vimentin upon induction of EMT by high-content imaging. In this review, we discuss the relevance of the chromobody technology with regard to the visualization of EMT-related processes in living systems. Cancer Res; 76(19); 5592–6. ©2016 AACR.

10 January 2019 in Antibodies
Verified
Journal Article
Open access
PDF file
BKBettina-Maria Keller
Bettina-Maria Keller
JMJulia Maier
Julia Maier
MWMelissa Weldle
Melissa Weldle
SSSoeren Segan
Soeren Segan
BTBjoern Traenkle
Bjoern Traenkle
Ulrich RothbauerUlrich Rothbauer
Ulrich Rothbauer
Single-domain antibodies have emerged as highly versatile nanoprobes for advanced cellular imaging. For real-time visualization of endogenous antigens, fluorescently labelled nanobodies (chromobodies, CBs) are introduced as DNA-encoded expression constructs in living cells. Commonly, CB expression is driven from strong, constitutively active promoters. However, high expression levels are sometimes accompanied by misfolding and aggregation of those intracellular nanoprobes. Moreover, stable cell lines derived from random genomic insertion of CB-encoding transgenes bear the risk of disturbed cellular processes and inhomogeneous CB signal intensities due to gene positioning effects and epigenetic silencing. In this study we propose a strategy to generate optimized CB expressing cell lines. We demonstrate that expression as ubiquitin fusion increases the fraction of intracellularly functional CBs and identified the elongation factor 1α (EF1-α) promoter as highly suited for constitutive CB expression upon long-term cell line cultivation. Finally, we applied a CRISPR/Cas9-based gene editing approach for targeted insertion of CB expression constructs into the adeno-associated virus integration site 1 (AAVS1) safe harbour locus of human cells. Our results indicate that this combinatorial approach facilitates the generation of fully functional and stable CB cell lines for quantitative live-cell imaging of endogenous antigens.

27 June 2025 in Science Advances
Verified
Journal Article
Open access
SPStefania Pezzana
Stefania Pezzana
SBSimone Blaess
Simone Blaess
BTBjoern Traenkle
Bjoern Traenkle
ASAnna Schaefer
Anna Schaefer
LRLara Ruoff
Lara Ruoff
DSDominik Sonanini
Dominik Sonanini
CD4 + T cells are crucial in shaping response and resistance to immunotherapy. To enhance our understanding of their multifaceted functions, we developed copper-64–radiolabeled nanobodies targeting the human CD4 receptor ( 64 Cu-CD4-Nb1) for positron emission tomography (PET). In human CD4-receptor knock-in mice, 64 Cu-CD4-Nb1 specifically accumulated in different orthotopic tumors, correlating with histological CD4 + cell densities. Based on intratumoral CD4 + cell distribution patterns within the core and periphery, we distinguished responders to combined αPD-1/4-1BB antibodies early on-treatment. CD4-PET identified resistance to αPD-1 monotherapy, which was mitigated by adding regulatory T cell–depleting α4-1BB antibodies. Patients with early-stage non–small cell lung cancer who relapsed after neoadjuvant αPD-L1 therapy revealed low CD4 + T cell densities in the tumor core. In human and mouse tumor tissues, regulatory T cells correlated with CD4 + cell densities. Thus, visualizing the spatial distribution patterns of CD4 + cells by PET offers mechanistic insights into CD4-mediated therapy efficacy, with great potential for guiding combinatorial immunotherapies in patients with cancer.

13 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMarius Gramlich
Marius Gramlich
SMSandra Maier
Sandra Maier
PKPhilipp D. Kaiser
Philipp D. Kaiser
BTBjoern Traenkle
Bjoern Traenkle
TWTeresa R. Wagner
Teresa R. Wagner
Anne ZeckAnne Zeck
Anne Zeck
N-linked glycosylation is a ubiquitous posttranslational modification of proteins. While it plays an important role in the biological function of proteins, it often poses a major challenge for their analytical characterization. Currently available peptide N-glycanases (PNGases) are often inefficient at deglycosylating proteins due to sterically inaccessible N-glycosylation sites. This usually leads to poor sequence coverage in bottom-up analysis using liquid chromatography with tandem mass spectrometry (LC-MS) and makes it impossible to obtain an intact mass signal in top-down MS analysis. In addition, most PNGases operate optimally only in the neutral to slightly acidic pH range and are severely compromised in the presence of reducing and denaturing substances, which limits their use for advanced bioanalysis based on hydrogen-deuterium exchange in combination with mass spectrometry (HDX-MS). Here, we present a novel peptide N-glycanase from Rudaea cellulosilytica (PNGase Rc) for which we demonstrate broad substrate specificity for N-glycan hydrolysis from multiply occupied and natively folded proteins. Our results show that PNGase Rc is functional even under challenging, HDX quench conditions (pH 2.5, 0 °C) and in the presence of 0.4 M Tris(2-carboxyethyl)phosphine (TCEP), 4 M urea and 1 M guanidinium chloride (GdmCl). Most importantly, we successfully applied the PNGase Rc in an HDX-MS workflow to determine the epitope of a nanobody targeting the extracellular domain of human signal-regulating protein alpha (SIRPα).

11 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
PKPhilipp Kaiser
Philipp Kaiser
SSSimon Straß
Simon Straß
SMSandra Maier
Sandra Maier
EHEvgenia Herbold
Evgenia Herbold
BTBjoern Traenkle
Bjoern Traenkle
Anne ZeckAnne Zeck
Anne Zeck
Background/Objectives: Developability assessment is a critical step in advancing antibody-based molecules toward clinical application. This evaluation typically begins during clinical candidate selection and continues throughout all modifications of the molecule during development. It is guided by the target product profile, which includes the intended administration route and regimen, formulation parameters, and process conditions encountered during manufacturing, storage, and delivery. While developability testing is well established for conventional therapeutic antibodies, strategies for assessing single-domain antibodies (sdAbs) and their conjugates remain underexplored. Here we present a strategy to test the developability of sdAbs as a case study for two clinical candidates intended as precursors for the production of diagnostic tracers for clinical imaging. Methods: Assays were developed to evaluate chemical and thermodynamic stability, target binding affinity and capacity, and chelation efficiency (“chelatability”). Accelerated stability studies were conducted for both unconjugated sdAbs and their chelator conjugated forms following incubation at two pH conditions, at multiple time points, and after twelve freeze-thaw cycles to simulate process conditions and long-term storage. Analytical assays were applied stepwise in a hierarchical approach to minimized experimental effort and material consumption. Candidates exhibiting critical developability features were selectively addressed by assays with increasing precision. Results: A tailored panel of analytical assays optimized for low molecular weight proteins was established and applied to the two clinical candidates, identifying instability hotspots as well as potential mitigation strategies. Successful engineering of a candidate with an initially critical developability profile was achieved. Conclusion: This study demonstrates the implementation of a structured developability assessment strategy for sdAb conjugates. The approach integrates physicochemical and functional stability evaluations, supporting robust candidate selection, formulation development, and method optimization for this class of molecules.